International Journal Chronic Obstructive Pulmonary Disease Dovepress Open Access Full Text Article open access scientiﬁc medical research O R I G I N A L R E S E A R C H Nasal highﬂow versus noninvasive ventilation patients chronic hypercapnic COPD This article published following Dove Press journal International Journal Chronic Obstructive Pulmonary Disease 1 3 2 Jens Bräunlich Dominic Dellweg Andreas Bastian Stephan Budweiser4 Winfried Randerath5 Dora Triché6 Martin Bachmann7 Christian Kähler8 Abdel Hakim Bayarassou9 Irmhild Mäder10 Jens Geiseler11 Norbert Köhler David Petroff Hubert Wirtz1 12 12 1Department Respiratory Medicine University Leipzig AöR Leipzig Germany 2Fachkrankenhaus Kloster Grafschaft GmbH Schmallenberg Grafschaft Germany 3PneumologieIntensivmedizinInfektiologie Marienkrankenhaus Kassel Kassel Germany 4Medizinische Klinik III RoMed Klinikum Rosenheim Rosenheim Germany 5Krankenhaus Bethanien gGmbH Klinik für Pneumologie und Allergologie Zentrum für Schlaf und Beatmungsmedizin Solingen Germany 6Department Respiratory Medicine Allergology Sleep Medicine Paracelsus Medical University Nuernberg General Hospital Nuernberg Nürnberg Germany 7Intensivmedizin und Beatmungsmedizin Klinik für Atemwegs Lungen und Thoraxmedizin Asklepios Klinikum Harburg Hamburg Germany 8Department Internal Medicine Innsbruck Medical University Innsbruck Austria 9Klinik für Pneumologie Kardiologie Schlaf und Beatmungsmedizin Malteser Krankenhaus Seliger Gerhard BonnRheinSieg Bonn Germany 10Zentralklinik Bad Berka GmbH Klinik für Pneumologie Bad Berka Germany 11Medizinische Klinik IV Klinikum Vest ParacelsusKlinik Marl Marl Germany 12Clinical Trial Centre Leipzig University Leipzig Leipzig Germany Correspondence Jens Bräunlich Department Respiratory Medicine University Leipzig AöR Liebigstrasse 20 Leipzig 04103 Germany Tel 49 341 971 2450 Email highﬂowwebde Background Despite encouraging results noninvasive ventilation NIV chronic hypercapnic COPD patients evident patients tolerate NIV beneﬁt We conducted study COPD patients stable chronic hyper capnia treated NIV nasal highﬂow NHF compare effectiveness Methods In multicentered randomized controlled crossover design patients received 6 weeks NHF ventilation followed 6 weeks NIV ventilation viceversa TIBICO 2011 2016 COPD patients stable daytime hypercapnia pCO250 mmHg recruited 13 German centers The primary endpoint pCO2 changes baseline blood gas lung function quality life QoL 6 min walking test duration device use secondary endpoints Results A total 102 patients meanSD age 65393 years 61 females body mass index 23148 kgm2 90 GOLD D pCO2 56554 mmHg randomized PCO2 levels decreased 47 n94 analysis set 95 CI 1875 P0002 NHF 71 95 CI 41101 P0001 baseline NIV indistinguishable intentiontotreat analysis The difference pCO2 changes devices 14 mmHg 95 CI 3104 P012 Both devices positive impact blood gases respiratory scores St Georges Respiratory Questionnaire Severe Respiratory Insufﬁciency Questionnaire Conclusions NHF constitute alternative NIV COPD patients stable chronic hypercapnia tolerating rejecting NIV respect pCO2 reduction improvement QoL Keywords noninvasive ventilation nasal highﬂow COPD hypercapnia Introduction Noninvasive ventilation NIV standard therapy ventilatory failure acute exacerbation COPD Increasing evidence effectiveness generated decades1 Studies demonstrated rapid improve ment blood gases reduction respiratory rate frequency intubation length hospital stay mortality2 Recent trials shown NIV beneﬁts COPD patients chronic hypercapnia35 A multicenter study 195 stable hypercapnic COPD patients revealed NIV decreases 1year mortality3 A study conﬁrmed reduced mortality additionally showed reduced rates exacerbation hospital readmission4 Other parameters improved NIV include hypercapnia oxygen saturation respiratory rate dyspnea 6min walking test 6MWTdistance quality life QoL3510 Despite encouraging results evident patients tolerate NIV beneﬁt it91113 submit manuscript wwwdovepresscom DovePress httpdoiorg102147COPDS206111 International Journal Chronic Obstructive Pulmonary Disease 201914 14111421 1411 2019 Bräunlich et al This work published licensed Dove Medical Press Limited The terms license available httpswwwdovepresscom termsphp incorporate Creative Commons Attribution Non Commercial unported v30 License httpcreativecommonsorglicensesbync30 By accessing work accept Terms Noncommercial uses work permitted permission Dove Medical Press Limited provided work properly attributed For permission commercial use work paragraphs 42 5 Terms httpswwwdovepresscomtermsphp Bräunlich et al Dovepress Nasal highﬂow NHF provides warmed humidi ﬁed gas administered slightly enlarged nasal prongs Oxygen fraction adjusted according clin ical requirements Nearsaturated humidity gas warmed body temperature allow tolerance high ﬂow rates NHF results small increases airway pressure mouth14 NHF opening reduced reduces minute volume respiratory rate lowers decreases work breathing1518 The exhaled gas upper airways rapidly washed physiological deadspace reduced1920 The high ﬂow rates delivered NHF sufﬁcient cover high peak inspiratory ﬂows avoiding admixture ambient air21 In recent study NHF superior standard nasal prongs SNP NIV patients severe hypoxemic respiratory failure regard intu bation rate mortality22 Reintubation rates NHF lower than2324 noninferior25 compared venturi mask SNP NIV respectively In addition mounting evidence NHF leads reduction partial pressure CO2 pCO2 reduction hypercapnic patients short periods152629 NHF successful reducing pCO2 small pilot trial 6 weeks27 Together CO2 washout studies1927 results led hypothesize NHF beneﬁt chronic hypercapnic COPD patients To test hypothesis conducted study COPD patients stable chronic hypercapnia treated crossover design NIV NHF 6 weeks The primary endpoint pCO2 reduction compared baseline Materials methods Study subjects COPD patients chronic respiratory insufﬁciency stable daytime hypercapnia pCO250 mmHg recruited 13 hospitals Germany Patients excluded type I II exacerbation30 4 weeks treated NIV 14 days body mass index higher 30 kgm2 The list inclusion exclusion criteria Supplementary materials section 2 All patients 18 years age provided written informed consent The study conducted accordance Declaration Helsinki Local institu tional review boards independent ethics committees approved protocol written informed consent obtained patients Ethical Committee Medical Faculty Leipzig University 12309ff The trial registered clinicaltrialsgov NCT02007772 Study design NHF NIV compared multicentered rando mized controlled 12week crossover trial randomized trolled trial RCT 6 weeks device Supplementary materials section 1 The primary goal provide estimate difference devices pCO2 change Methods Patients randomly assigned receive NHF NIV ﬁrst Randomization performed centrally Clinical Trial Center Leipzig block randomization variable block length stratiﬁed trial site For NHF TNI 20 oxy nasal prongs medium bore outlets TNI Medical AG Wuerzburg Germany A ﬂow rate 20 Lmin stipulated study protocol oxygen supplementation chan ged compared baseline spontaneous breathing oxygen nasal cannula At time study inception NHF devices delivered 20 Lmin All centers instructed follow German guidelines humidiﬁcation NIV pressure settings It general aim adjust pressures achieve optimal tolerability pCO2 reduction31 The preferred interface oronasal mask nasal mask case intolerance Trial sites free choose preferred NIV listed Table S1 Patients advised use NIV NHF 6 hrs day preferably sleep usage daytime accepted Duration ventilation based devices usage data Analysis The primary endpoint change pCO2 baseline end NIV NHF treatment The secondary endpoints changes capillary blood gases lung function Supplementary materials section 4 6MWT QoL compliance The rationale motivated trial intrinsically noninferiority NHF Because paucity data lack consensus margins equivalence context chose descriptive estimates primary ana lysis noninferiority test secondary analysis The sample size determination followed accordingly Based 1412 submit manuscript wwwdovepresscom DovePress International Journal Chronic Obstructive Pulmonary Disease 201914 Dovepress Bräunlich et al expected SD 11 paired differences taken pilot data sample size 70 patients required 95 CI spanning width 6 baseline value difference paired means coverage corrected nQuery 602 Taking dropout account recruitment 100 patients planned study A test noninferiority NHF margin 5 mm Hg speciﬁed statistical plan secondary analysis based mean treatment effects trials available time332 The analysis set intention treat included patients started treatment pCO2 values 50 mm Hg screening 45 mm Hg baseline The protocol set includes essentially patients received devices sufﬁciently Supplementary materials section 3 precise deﬁnition Missing data accounted multiple imputation Supplementary materials section 4 Outcomes analyzed mixed model repeated measures patient random variable The difference NHF NIV devices estimated 95 CI In sensitivity analysis mixed model applied non imputed data In second sensitivity analysis trial center included random term A paired ttest compare duration device usage For data analysis graphic presentation software package R version 341 pCO250 mmHg Results Patients From May 2011 November 2016 102 patients randomized 94 included intention treat analysis Figure 1 Since pCO2 levels ﬁve randomized patients screening decreased 45 mmHg baseline indication treatment longer given Three patients withdrew trial receiving ﬁrst treatment The protocol set contained 53 patients similar demographic characteristics baseline pCO2 values analysis set Baseline characteristics presented Table 1 list concomitant diseases medica tions Tables S2 S3 All patients history lasting NIV treatment long term oxygen therapy Treatments A total 91 patients began NHF treatment ﬂow rate 19806 Lmin O2 insufﬂation 2209 Lmin 82 patients began NIV treatment oronasal mask 57 nasal mask 21 1 Three patients tolerate NIV early terminated use ﬁrst 24 hrs An additional 11 patients termi nated use NIV early device related diseaserelated studyrelated reasons Sixteen patients terminated use NHF early device related ﬁve diseaserelated ﬁve studyrelated reasons Mean inspiratory expiratory positive airway pressures IPAP EPAP 20536 cm H2O 4612 cm H2O respectively O2 rate 2007 Lmin 13339 breathsmin ST mode n73 Data time available 70 NHF devices 77 54 NIV devices 66 47 patients Mean duration NHF usage 5233 hrs day compared 3925 hrsday NIV The mean difference 16 hrsday 95 CI 0924 P0001 NHF versus NIV Figure S1 Primary secondary endpoints PCO2 levels decreased 28 mm Hg 95 CI 1146 47 95 CI 1875 NHF 42 mm Hg 95 CI 2460 71 95 CI 41101 baseline NIV The difference pCO2 changes devices 14 mmHg 95 CI 3104 minus sign indicates NIV stronger effect Table 2 This difference lies noninferiority margin 5 mm Hg P0001 Sensitivity analyses demon strated completer case analysis intro duction random effect centers alters result meaningfully In protocol set pCO2 levels decreased 29 mmHg 43 mmHg NHF NIV respectively difference pCO2 changes devices 13 95 CI 3004 mmHg indistinguishable analysis set There indication order devices relevant P059 Blood samples taken median 70 hrs IQR 4687 stopping use device A considerable reduction pCO2 5 mm Hg reached 37 patients NHF use 52 NIV use However increases pCO2 observed 26 NHF 22 NIV Figure 2 An explora tory analysis reasons goodpoor response section 5 Supplementary materials PO2 spirometry 6MWT QoL listed Table 2 Changes baseline tended small pO2 spirometry 6MWT signiﬁcant clinically meaningful QoL While NHF 61 International Journal Chronic Obstructive Pulmonary Disease 201914 submit manuscript wwwdovepresscom DovePress 1413 Bräunlich et al Dovepress Enrolment Screened n515 Not meeting inclusion criteria n379 Declined participate n28 Other reasons n6 Recruited n102 fulfilled inclusion criteria screening Randomization Initial allocation Allocated NHF n51 Allocated NIV n51 Withdrew n3 pCO2 45 mm Hg baseline n4 pCO2 45 mm Hg baseline n1 First intervention Began NHF n44 Began NIV n50 Died n1 Withdrew n7 Went health spa n1 Lost contact n1 Refused switch devices n2 Withdrew n2 Physician chose switch devices n1 CrossOver Began NIV n32 Began NHF n47 Died n2 Lung transplant n1 Withdrew n3 Died n1 Lung transplant n1 Withdrew n4 Complete pCO2 data n26 Complete pCO2 data n41 Data Analysis Full analysis set n44 began NHF Full analysis set n50 began NIV Per protocol set n24 Per protocol set n29 Due mixup patient received devices wrong order Figure 1 Flowchart enrolment device usage patients analyzed Abbreviations NHF nasal highﬂow NIV noninvasive ventilation PCO2 partial pressure carbon dioxide capillary blood patients improved St Georges Respiratory Questionnairetotal scores 4 points similar 54 NIV Differences endpoints listed Table 2 generally signiﬁ NHF NIV Safety Four patients died trial NHF NIV Supplementary materials section 7 Other adverse events listed according device onset event Table 3 1414 submit manuscript wwwdovepresscom DovePress International Journal Chronic Obstructive Pulmonary Disease 201914 Dovepress Bräunlich et al Table 1 Baseline demographic clinical characteristics Females Age years BMI kgm2 BMI 185 185 BMI 25 BMI 25 Heart rate bpm Sixminute walking test m N94 57 61 65393 23148 20 21 37 39 37 39 823129 236135 Time COPD diagnosis years 71 33 117 Smoking Current smoker Exsmoker Never smoked 19 21 69 77 2 2 Number pack years 40 28 51 Number exacerbations 12 monthsa 0 exacerbations 12 exacerbations 3 exacerbations Number hospital stay CAT score GOLD classiﬁcation 2011 D C B A O2 insufﬂation Lmin Capillary pCO2 mmHg Capillary pO2 mmHg pH Base excess BE mmolL HCO3 FEV1 predicted FVC predicted FEV1FVC Respiratory rate breathsmin mmolL 1822 24 26 46 51 21 23 1216 24776 79 90 6 7 3 3 2009 56554 689160 73990036 8438 32132 285102 480150 494134 20755 Notes Values numbers mean SD median interquartile range aData unavailable 3 patients Abbreviation BMI body mass index Discussion In randomized controlled multicentered crossover trial NHF similarly effective NIV modest improvements capillary pCO2 groups slight tendency favor NIV This ﬁrst RCT providing evidence NHF effective COPD patients stable chronic hypercapnia NHF NIV reduced capillary pCO2 28 mmHg 47 42 mmHg 71 respectively These results NIV correspond Köhnlein et al3 capillary pCO2 lowered 74 1 year treatment differed 51 control group A recent trial Murphy et al4 observed similar reductions pCO2 62 mmHg 6 weeks Most studies NHF excluded hypercapnic patients studied population containing normo hypercapnic patients little reduction pCO2232533 Studies exploring effect NHF pCO2 purely hypercapnic patients1516262834 suggest dependence baseline pCO2 value expected1634 A recent study compared longterm oxygen therapy LTOT NHF 29 stable hypercapnic COPD patients NHF inhibited LTOTinduced increase pCO2 improved QoL35 Another recent study demonstrated unaltered lung function COPD patients brief NHF use29 In studies hypercapnic patients blood gas samples taken NHF treatment immediately thereafter15162627 In trial blood gases taken minimum 3 hrs following respiratory support reﬂect situation outpatient clinic b provide data lasting effects However lag period result smaller treatment effects compared stu dies shorter intervals1627 In previous similarly designed pilot study similar delay observed pronounced pCO2 reduction NHF NIV27 It plausible pCO2 rises day nighttime use respiratory support The mentioned NIV trials chronic hypercapnic COPD patients designed 1hr delay NIV use blood gas analysis34 Changes secondary endpoints similar devices suggest effective respiratory support COPD patients In particular improvements QoL wellestablished beneﬁt NIV9 comparable NHF treatment The respiratory rate reduced NHF The 6MWTdistance increased devices signiﬁcant NHF Changes hospitalizations assessed 6week time frame We present individual patient data capillary pCO2 waterfall plot demonstrating large variance individual response providing data numbers exacerbation rates International Journal Chronic Obstructive Pulmonary Disease 201914 submit manuscript wwwdovepresscom DovePress 1415 I V N s v F H N I V N d n F H N n e e w t e b e u l v P e g n h c n e c n e r e f f D e u l v P V N I I V N g n s u e g n h C Bräunlich et al Dovepress 6 7 0 0 5 1 0 2 1 0 7 7 0 5 5 0 4 1 0 6 5 0 0 6 8 0 8 2 0 0 3 0 2 4 0 3 3 0 0 3 6 0 2 3 0 3 5 0 4 1 0 1 3 0 0 5 0 2 9 0 8 2 0 7 3 0 7 5 0 5 6 0 3 9 0 d e u n t n o C 0 5 0 7 2 o t 1 7 o t 1 0 1 1 3 1 0 3 4 0 o t 1 3 4 1 9 3 o t 3 5 7 0 8 0 o t 4 1 3 0 2 0 o t 2 1 5 0 0 0 o t 4 1 7 0 1 0 0 o t 1 0 0 0 0 0 2 4 o t 5 2 o t 3 3 o t 2 1 8 0 6 2 5 1 9 0 3 0 9 9 0 o t 0 8 0 9 8 0 9 0 2 o t 7 2 1 3 0 1 o t 4 3 1 4 5 3 8 0 1 o t 7 8 0 7 9 0 2 5 o t 8 0 2 2 6 0 3 o t 0 0 1 3 0 1 1 2 o t 3 4 1 1 8 3 o t 2 4 2 0 0 2 o t 8 6 4 2 4 2 o t 3 6 9 1 0 6 o t 1 4 o t 7 3 o t 3 3 5 2 4 3 3 1 8 0 2 0 5 1 o t 1 3 8 0 5 1 0 0 4 8 0 1 0 0 0 4 7 0 8 9 0 1 0 0 0 1 0 0 0 9 5 0 7 2 0 0 2 1 0 3 4 0 2 7 0 3 8 0 0 4 0 5 6 0 6 1 0 3 1 0 0 5 8 0 0 0 2 0 0 4 2 0 0 5 8 0 2 9 0 0 7 2 0 0 5 2 0 0 1 4 0 3 1 o t 6 1 1 0 0 9 o t 0 1 0 5 4 2 o t 0 6 2 4 3 5 o t 1 1 o t 8 3 1 1 8 0 0 0 3 1 5 1 o t o t 7 2 0 2 9 2 2 2 1 0 0 o t 1 0 0 1 0 0 2 5 o t 6 0 3 2 2 4 o t 8 1 2 1 7 3 o t 2 0 0 2 9 0 1 o t 9 8 0 8 9 0 5 8 1 o t 9 4 1 6 9 o t 9 3 8 1 9 2 5 1 1 o t 1 9 0 3 0 1 5 5 o t 9 0 3 2 5 5 4 o t 5 5 5 5 2 1 6 o t 4 0 8 2 8 8 o t 8 0 8 4 5 9 o t 7 0 1 5 9 3 o t 8 4 4 0 7 8 o t 7 0 0 4 0 5 o t 1 2 5 1 1 7 o t 4 0 7 3 e u l v P F H N 6 4 0 0 3 3 0 0 2 0 0 0 3 5 0 3 5 0 1 0 0 0 1 0 0 0 9 9 0 8 5 0 1 2 0 7 5 0 4 6 0 0 9 7 0 6 8 0 1 3 0 8 9 0 4 1 0 8 1 0 0 5 1 0 0 0 1 0 0 0 8 4 0 6 2 0 8 7 0 0 6 4 0 0 5 o t 3 0 7 2 9 3 0 0 0 F H N g n s u e g n h C e n l e s B s e m o c t u o y r d n o c e s d n y r m r P 2 l e b T s r e t e m r p l l c g o o s y h p c s B 0 0 o t 9 2 4 1 0 6 o t 0 2 0 2 1 1 o t 6 4 8 2 0 6 o t 4 1 o t 1 3 7 0 4 1 3 0 7 0 8 0 o t o t 2 2 5 1 2 2 5 1 1 0 0 o t 1 0 0 0 0 0 7 3 o t 8 2 o t 9 3 o t 1 2 6 0 2 2 8 0 1 1 9 0 4 4 1 o t 0 9 1 3 2 2 2 1 o t 9 9 0 0 1 1 2 6 o t 3 7 6 0 9 1 1 o t 5 9 0 6 0 1 2 3 o t 2 3 0 0 2 5 3 o t 8 4 2 5 1 2 7 o t 7 0 9 3 0 9 o t 0 1 0 5 9 1 1 o t 1 3 5 7 9 5 o t 4 7 o t 3 6 o t 9 4 o t 8 2 0 2 3 0 2 2 5 1 7 2 0 3 3 1 8 5 o t 1 1 5 3 3 0 2 0 2 8 5 6 5 9 8 6 7 3 9 4 8 1 2 3 0 4 7 9 7 4 4 8 2 1 0 5 7 1 0 3 2 4 4 2 2 1 8 1 6 9 7 2 1 7 3 0 3 3 2 8 3 4 1 2 3 6 4 5 9 7 6 4 4 5 1 3 5 6 7 4 6 0 5 n m s h t e r b e t r y r o t r p s e R n m s t e b e t r t r e H L l o m m s s e c x e e s B L l o m m 3 O C H g H m m 2 O C p g H m m 2 O p 2 O S s s y l n s g d o o B l y r t e m o r p S H p d e t c d e r p C V F d e t c d e r p 1 V E F d e t c d e r p t o t R d e t c d e r p V R C V F 1 V E F d e t c d e r p C L T V R t n e m s s e s s e l c s u m y r o t r p s e R d e t c d e r p 1 0 P d e t c d e r p x m P I m t s e t g n k l w e t u n m x S p e e S l d n s m o t p m y S t n d n e t t A s t n l p m o C y r o t r p s e I R R S g n n o t c n u F l c s y h P g n e B l l e W l l c g o o h c y s P s p h s n o t l e R l c o S y t e x n A g n n o t c n u F l c o S e l c S y r m m u S 1416 submit manuscript wwwdovepresscom DovePress International Journal Chronic Obstructive Pulmonary Disease 201914 Dovepress Bräunlich et al I V N s v F H N I V N d n F H N n e e w t e b e u l v P e g n h c n e c n e r e f f D 2 9 0 2 9 0 2 7 0 2 6 0 6 9 0 5 6 0 1 8 0 9 2 0 6 5 o t 5 3 o t 0 5 2 3 3 0 2 0 1 3 o t 5 4 7 0 0 2 o t 4 3 7 0 5 0 o t 8 0 1 0 6 0 o t 6 0 0 0 7 0 o t 9 0 1 0 2 0 o t 4 0 2 0 e u l v P V N I 1 0 0 0 1 1 0 0 0 1 0 0 0 4 1 0 0 7 4 0 9 1 0 7 2 0 0 I V N g n s u e g n h C 3 6 o t 9 6 1 6 1 1 9 0 o t 6 7 2 4 6 2 o t 3 0 1 5 6 2 4 o t 6 9 9 6 4 0 o t 8 0 2 0 2 0 o t 0 1 4 0 7 1 o t 1 0 9 0 e u l v P F H N 1 0 0 0 5 3 0 0 0 1 0 0 0 1 1 0 0 5 4 0 9 3 0 5 1 0 0 F H N g n s u e g n h C e n l e s B 6 6 o t 2 7 1 9 1 1 0 1 0 2 5 3 o t o t o t 8 7 4 4 7 9 8 5 9 8 2 6 4 0 o t 8 0 2 0 4 0 o t 9 0 3 0 8 1 o t 2 0 0 1 7 2 7 5 4 8 3 7 5 1 8 6 4 4 9 5 7 3 h t l e h f o e t t s g n d r g e r S A V s e c v e D f o t n e m s s e s s A e l c S g r o B d e ﬁ d o M k l w n m 6 e r o f e B k l w n m 6 r e t f A s m o t p m y S y t v t c A s t c p m I l t o T Q R G S d e u n t n o C 2 l e b T o w t e h t f o o t r s l n m u o c l n ﬁ e h T l d o f 0 1 1 d e g n h c t F H N g n s u d n e u l v d e t c d e r p e h t f o 7 1 0 3 s t o t R f o e u l v e n l e s b e h t e e n l e s b o t t c e p s e r h t l w e g n h c d o f n n o t r e f e r s n m u o c l s e g n h c e s e h T I C 5 9 e r s t e k c r b n s r e b m u N s e t o N respond poorly A similar spectrum responses described comparably clear fashion mentioned literature34111235 The SD observed pCO2 changes roughly comparable reported studies observed similar spectrum suggesting responses Many clinicians agree patient beneﬁt NIV However dependable criteria predicting success3411131632 We non responders roughly comparable numbers devices Exploratory analyses showed variety demographic diseasespeciﬁc markers asso ciated extent pCO2 response A non negligible minority patients higher levels pCO2 ventilatory support compared beginning study Such responses derive fact performed real life study health chronically ill patients deteriorate despite use noninvasive respiratory support It important note study NHF administered relatively moderate ﬂow 20 Lmin state art trial conception This trial demonstrates NHF ﬂow 20 Lmin good treatment option stable hypercapnic COPD patients However likely treatment higher ﬂow rates result improvements1627 An important prerequisite effective treatment COPD patients NIV choice sufﬁcient pressure difference combined respiratory rate control adequate duration treatment3536 In regard settings applied trial slightly different applied studies Murphy et al median IPAP 24 cmH2O EPAP 4 cm H2O respiratory rate 14min Köhnlein et al mean IPAP 216 cmH2O EPAP 48 cmH2O respiratory rate 16min34 In trial NHF NIV average 52 hrsday data available 77 patients 39 hrsday 66 patients respectively In study Köhnlein et al NIV 59 hrsday 47 patients Murphy et al reported mean use 47 hrsday 84 patients comparable 6 weeks When compared NIV longer use NHF tolerance observed A number studies demonstrated improved comfort NHF devices162337 indicate better trial Earlier studies indicated NIV effective redu cing pCO2 patients stable hypercapnia3432 In particular hypercapnia reversible acute exacerbation3238 uncertain NIV n o t l t n e v e v s v n n o n V N I w o ﬂ h g h l s n F H N e r n n o t s e u Q y c n e c ﬁ f u s n I y r o t r p s e R e r e v e S I R S e r n n o t s e u Q y r o t r p s e R s e g r o e G t S Q R G S s n o t v e r b b A 5 0 0 p f o e v t t n e s e r p e r e r s e u l v d o B l 0 8 n t h t o s s e r n n o t s e u q e h t e t u b r t s d t o n d d s r e t n e c l r t e h t f o e n o Q R G S d n I R S r o F d e s u s w 4 9 n t e s s s y l n l l u f e h t g n n e m n o t t u p m n o d e s b e r e b t l s h t n s e s y l n e h T s e g n h c International Journal Chronic Obstructive Pulmonary Disease 201914 submit manuscript wwwdovepresscom DovePress 1417 Bräunlich et al Dovepress g H m m e n l e s b p u w o l l o F 2 O C p 0 2 5 1 0 1 5 0 5 0 1 5 1 0 2 0 2 5 1 0 1 5 0 5 0 1 5 1 0 2 Correlation 065 048 077 Worsening Improvement F H N I V N Patients Figure 2 Waterfall plot depicting individual change carbon dioxide levels capillary blood pCO2 intervention Notes NHF nasal highﬂow NIV noninvasive ventilation ΔpCO2 difference partial pressures carbon dioxide capillary blood baseline followup Each bar represents ΔpCO2 single patient grey lines patients upper lower halves correspond grey line connects given patient crossover The correlation coefﬁcient changes NHF NIV 95 CI shown patients devices added beneﬁt Our minimum 4week exacer bationfree interval chosen exclude transient hyper capnia time inclusion study Limitations study include lower usage times NIV slightly lower pressure difference IPAPEPAP com pared previous studies34 use NHF device restriction 20 Lmin ﬂow This inﬂuenced efﬁcacy devices Moreover trial registered onequarter patients recruited data usage time incomplete blinding possible Strengths study cross design demonstration lasting effect exclusion patients transient hypercapnia following exacerbation 1418 submit manuscript wwwdovepresscom DovePress International Journal Chronic Obstructive Pulmonary Disease 201914 Dovepress Bräunlich et al Table 3 There total 38 nonlethal SAEs 21 patients 9 NHF 8 NIV 4 patients devices elucidate question pCO2 reduction translate beneﬁt survival clinical outcomes NHF NIV Death Number SAEs nonlethal Respiratory Dyspnoea Exacerbation Atelectasis Hypercapnic respiratory failure Mechanical ventilation Pneumonia Pneumothorax spontaneous Pulmonary failure Respiratory acidosis Cardiac Myocardial infarction Decompensation Panic attack Other Number AEs SAEs Respiratorypossibly related device Aerophagia Bronchitis acute Claustrophobia Coldness local Conjunctivitis COPD exacerbation Dyspnoea Ear problem Epistaxisnasal drynessnasal irritation Hemoptysis Insomnia Middle ear disorder Oral thrush Panic attacks Rib pain Cardiac Decompensation Tachycardia Signs rightheart failure Other 2 17 11 1 1 1 1 1 1 33 1 13 5 1 1 1 1 1 1 4 4 2 21 1 7 1 1 1 1 1 2 7 55 5 1 1 1 13 3 1 2 1 1 1 1 1 7 16 Abbreviations SAE adverse event NHF nasal highﬂow NIV noninvasive ventilation In summary shown NHF repre sent alternative NIV chronic hypercapnic COPD patients comparable effectiveness Future studies Abbreviations list pCO2 partial pressure carbon dioxide pO2 par tial pressure oxygen 6MWT 6min walking test EPAP expiratory positive airway pressure IPAP inspira tory positive airway pressure LTOT longterm oxygen therapy NHF nasal highﬂow NIV noninvasive ventila tion QoL quality life RCT randomized controlled trial SNP standard nasal prongs Data sharing statement The authors share statistical analysis plan study protocol request An online supplement avail able The data available 5 years Further data shared qualiﬁed request particular meta analyses individual patient metaanalyses In case requesting data asked provide copy institutional review board approval metaanalysis registered public registry Acknowledgments This study investigatorinitiated project supported TNI Medical AG grants provision equipment The sponsor role design conduct study collection management analysis interpreta tion data preparation review approval manuscript decision submit manuscript Author contributions All authors contributed data analysis drafting revising paper gave ﬁnal approval version published agree accountable aspects work Disclosure Dr Bräunlich reports grants nonﬁnancial support TNI Medical AG conduct study grants personal fees nonﬁnancial support TNI Medical AG personal fees FisherPaykel outside sub mitted work Prof Kähler reports nonﬁnancial support TNI Medical AG Prof Randerath reports grants Heinen und Löwenstein Weinmann Philips Respironics Inspire outside submitted work Prof Wirtz reports personal fees nonﬁnancial support TNI Medical AG conduct study All authors disclose International Journal Chronic Obstructive Pulmonary Disease 201914 submit manuscript wwwdovepresscom DovePress 1419 Bräunlich et al References 1 Brochard L Isabey D Piquet J et al Reversal acute exacerbations chronic obstructive lung disease inspiratory assistance face mask N Engl J Med 19903232215231530 doi101056 NEJM199011293232204 2 Osadnik CR Tee VS CarsonChahhoud KV Picot J Wedzicha JA Smith BJ Noninvasive ventilation management acute hypercapnic respiratory failure exacerbation chronic obstructive pulmonary disease Cochrane Database Syst Rev 20177CD004104 doi10100214651858CD003881pub4 3 Köhnlein T Windisch W Köhler D et al Noninvasive positive treatment severe stable chronic pressure ventilation obstructive pulmonary disease prospective multicentre rando mised trial Lancet Respir Med 20142 9698705 doi101016S2213260014701535 controlled clinical 4 Murphy PB Rehal S Arbane G et al Effect home noninvasive ventilation oxygen therapy vs oxygen therapy hospital death readmission acute COPD exacerbation JAMA 20173172121772186 randomized clinical doi101001jama20175254 trial 5 Dreher M Storre JH Schmoor C Windisch W Highintensity versus lowintensity noninvasive ventilation patients stable hyper capnic COPD randomised crossover trial Thorax 201065 4303308 doi101136thx2009124263 6 Díaz O Bégin P Andresen M et al Physiological clinical effects diurnal noninvasive ventilation hypercapnic COPD Eur Respir J 200526610161023 doi101183090319360500033905 7 Windisch W Quality life home mechanical ventilation study group Impact home mechanical ventilation healthrelated quality life Eur Respir J 200832513281336 doi1011830903193600066407 8 Budweiser S Hitzl AP Jörres RA Schmidbauer K Heinemann F Pfeifer M Healthrelated quality life longterm prognosis chronic hypercapnic respiratory failure prospective survival analysis Respir Res 20078110251029 doi1011861465 9921891 9 Tsolaki V Pastaka C Karetsi E et al Oneyear noninvasive ventila tion chronic hypercapnic COPD effect quality life Respir Med 20081026904911 doi101016jrmed200804008 10 Wijkstra PJ Noninvasive positive pressure ventilation NIPPV stable patients chronic obstructive pulmonary disease COPD Respir Med 2003971010861093 doi101016S095461110300163X 11 Chan VL Chu CM Compliance home noninvasive ventilation Respirology 2012174735736 doi101111j14401843201202169x 12 Tissot A Jaffre S Gagnadoux F et al Home noninvasive ventilation fails improve quality life elderly results multicenter cohort study doi101371journal 20151010e0141156 pone0141156 PLoS One 13 Nava S Gregoretti C Interfaces humidiﬁcation noninvasive mechanical ventilation Respir Care 20095417184 14 Parke RL McGuinness SP Eccleston ML A preliminary randomized controlled trial assess effectiveness nasal highﬂow oxygen intensive care patients Respir Care 2011563265270 doi104187 respcare00801 15 Bräunlich J Beyer D Mai D Hammerschmidt S Seyfarth HJ Wirtz H Effects nasal high ﬂow ventilation volunteers COPD idiopathic pulmonary ﬁbrosis patients Respiration 2013854319325 doi101159000342027 16 Bräunlich J Köhler M Wirtz H Nasal highﬂow improves ventilation patients COPD COPD 20161110771085 doi102147COPD 17 Biselli PJC Kirkness JP Grote L et al Nasal highﬂow therapy reduces work breathing compared oxygen sleep COPD smoking controls prospective observational study J Appl Physiol 201712218288 doi101152japplphysiol002792016 Dovepress 18 Delorme M Bouchard PA Simon M Simard S Lellouche F Effects highﬂow nasal cannula work breathing patients recovering acute respiratory failure Crit Care Med 2017451219811988 doi101097CCM0000000000002693 19 Möller W Feng S Domanski U et al Nasal high ﬂow reduces dead space J Appl Physiol 20171221191197 doi101152 japplphysiol005842016 20 Bräunlich J Goldner F Wirtz H Nasal highﬂow eliminates CO2 20172428688 airways Respir Physiol Neurobiol lower doi101016jresp201703012 21 Wagstaff TAJ Soni N Performance types oxygen delivery devices varying respiratory rates Anaesthesia 2007625492503 doi101111j13652044200705026x 22 Frat JP Thille AW Mercat A et al Supplementary appendix highﬂow oxygen nasal cannula acute hypoxemic respira tory failure N Engl J Med 20153722321852196 doi101056 NEJMoa1503326 23 Maggiore SM Idone FA Vaschetto R et al Nasal highﬂow versus venturi mask oxygen therapy extubation Effects oxygenation comfort clinical outcome Am J Respir Crit Care Med doi101164rccm201402 0364OC 20141903282288 24 Hernández G Vaquero C González P et al Effect postextubation highﬂow nasal cannula vs conventional oxygen therapy reintuba tion lowrisk patients randomized clinical trial JAMA 2016315 1313541361 doi101001jama20162711 25 Hernández G Vaquero C Colinas L et al Effect postextubation highﬂow nasal cannula vs noninvasive ventilation reintubation postextubation respiratory failure highrisk patients trial JAMA 20163161515651574 randomized clinical doi101001jama201614194 26 Pisani L Fasano L Corcione N et al Change pulmonary mechanics effect breathing pattern high ﬂow oxygen therapy stable hypercapnic COPD Thorax 2017724373375 doi101136thoraxjnl2016209673 27 Bräunlich J Seyfarth HJ Wirtz H Nasal highﬂow versus noninvasive ventilation stable hypercapnic COPD preliminary report Multidiscip Respir Med 201510127 doi101186s402480150019y 28 Jeong JH Kim DH Kim SC et al Changes arterial blood gases use highﬂow nasal cannula therapy ED Am J doi101016j Emerg ajem201507060 2015331013441349 Med 29 Vogelsinger H Halank M Braun S et al Efﬁcacy safety nasal highﬂow oxygen COPD patients BMC Pulm Med 201717 118 30 Anthonisen NR Manfreda J Warren CP Hershﬁeld ES Harding GK Nelson NA Antibiotic therapy exacerbations chronic obstruc tive pulmonary disease Ann Intern Med 19871062196204 doi107326000348191062196 31 Windisch W Walterspacher S Siemon K Geiseler J Sitter H German society pneumology Guidelines noninvasive invasive mechanical ventilation treatment chronic respira tory failure published german society pneumology DGP Pneumologie 20106410640652 doi101055s0030 1255558 32 Struik FM Sprooten RTM Kerstjens HAM et al Nocturnal noninvasive ventilation COPD patients prolonged hypercap failure nia randomised controlled parallelgroup study Thorax 201469 9826834 doi101136thoraxjnl2013203884 respiratory ventilatory support acute 33 Frat JP Thille AW Mercat A et al Highﬂow oxygen nasal cannula acute hypoxemic respiratory failure N Engl J Med 20153722321852196 doi101056NEJMoa1503326 34 Bräunlich J Wirtz H NHF hypercapnia brief look Respirology 201722610491050 doi101111resp13092 1420 submit manuscript wwwdovepresscom DovePress International Journal Chronic Obstructive Pulmonary Disease 201914 Dovepress Bräunlich et al 35 Nagata K Kikuchi T Horie T et al Domiciliary highﬂow nasal cannula oxygen therapy stable hypercapnic COPD patients multicenter randomized crossover trial Ann Am Thorac Soc 2018154432439 doi101513AnnalsATS201706425OC 36 Murphy PB Davidson C Hind MD et al Volume targeted versus pressure support noninvasive ventilation patients super obesity chronic respiratory failure randomised controlled trial Thorax 2012678727734 doi101136thoraxjnl2012201768 37 Cuquemelle E Pham T Papon JF Louis B Danin PE Brochard L Heated humidiﬁed highﬂow oxygen therapy reduces discomfort respiratory failure Respir Care 201257 hypoxemic 1015711577 doi104187respcare01681 38 Costello R Deegan P Fitzpatrick M McNicholas WT Reversible hypercapnia chronic obstructive pulmonary disease distinct pat tern respiratory failure favorable prognosis Am J Med 19971023239244 doi101016S000293439700017X International Journal Chronic Obstructive Pulmonary Disease Dovepress Publish work journal The International Journal COPD international peerreviewed journal therapeutics pharmacology focusing concise rapid reporting clinical studies reviews COPD Special focus given pathophysiological processes underlying disease inter vention programs patient focused education self management protocols This journal indexed PubMed Central MedLine CAS The manuscript management completely online includes quick fair peerreview easy use Visit httpwwwdovepresscomtestimonialsphp read real quotes published authors Submit manuscript httpswwwdovepresscominternationaljournalofchronicobstructivepulmonarydiseasejournal International Journal Chronic Obstructive Pulmonary Disease 201914 submit manuscript wwwdovepresscom DovePress 1421